Marinus Pharmaceuticals Inc (MRNS) - News Archive

Marinus Pharmaceuticals, Inc. a trailblazer in the development of innovative treatments for seizure disorders, has made significant strides recently, showcasing its commitment to advancing therapies for patients in need...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics targeting seizure disorders, has made significant strides in its clinical programs and is po...

In recent months, the performance of Marinus Pharmaceuticals Inc shares has been trailing behind the overall market. This can be attributed to various factors, including recent news events that have influenced investor...

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), a biopharmaceutical company specializing in innovative therapies for neuropsychiatric disorders, has recently found itself at the center of a class action lawsuit. Filed by...

Marinus Pharmaceuticals, a leading pharmaceutical company focused on developing innovative therapies for seizure disorders, recently announced the approval of ganaxolone oral suspension by the China National Medical Pro...

Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has been experiencing a challenging quarter with its shares underperforming the market. The company s year-to-date performance has also fallen short, lacking an 18% increase s...

As the deadline for investor claims against Marinus Pharmaceuticals approaches, several law firms have launched investigations and filed class action lawsuits on behalf of shareholders who suffered significant losses in...

Marinus Pharmaceuticals Inc, a prominent pharmaceutical company, has recently been experiencing a decline in share performance, trailing behind the overall market. This article aims to analyze the events surrounding thi...

On June 27, 2024, Levi & Korsinsky announced the filing of a securities class action lawsuit against Marinus Pharmaceuticals, Inc. (MRNS). The lawsuit seeks to recover losses of shareholders who were adversely affected...

Marinus Pharmaceuticals Phase 3 RAISE Trial of IV Ganaxolone Shows Promising Results for Refractory Status Epilepticus Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), renowned for its pioneering work in the realm of seizu...

In a recent press release, Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) has announced significant advancements in its research and development efforts for the treatment of seizures associated with tuberous sclerosis comp...

In an integral new development, Marinus Pharmaceuticals, Inc., a pharmaceutical corporation focusing on crafting innovative therapeutics for seizure disorders, announced its proactive involvement in a major global healt...